Structural and functional consequences of buserelin-induced enteric neuropathy in rat

BMC Gastroenterology

Bodil Ohlsson²  Eva Ekblad¹  Peter Bonn³  Björn Weström⁴  Bodil Roth²  Elin Sand¹ 

[1] Department of Experimental Medical Science, Neurogastroenterology Unit, BMC B11, Lund University, Lund, 221 84, Sweden;Department of Clinical Sciences, Division of Internal Medicine Skåne University Hospital, Lund University, Inga Marie Nilssons street 32, Malmö, S-205 02, Sweden;Department of Medicinal Chemistry, CVMD, AstraZeneca, Mölndal, Sweden;Department of Biology, Functional Biology, Lund University, Lund, 221 00, Sweden

关键词: Somatostatin;    Luteinizing hormone (LH);    Gonadotropin-releasing hormone (GnRH);    Gastrointestinal (GI) tract;    Enteric subpopulations;    Enteric neuropathy;   

Others  :  1121740
DOI  :  10.1186/s12876-014-0209-7

 received in 2014-09-10, accepted in 2014-11-28,  发布年份 2014

【 摘 要 】

Background

Women treated with gonadotropin-releasing hormone (GnRH) analogs may develop enteric neuropathy and dysmotility. Administration of a GnRH analog to rats leads to similar degenerative neuropathy and ganglioneuritis. The aim of this study on rat was to evaluate the early GnRH-induced enteric neuropathy in terms of distribution of neuronal subpopulations and gastrointestinal (GI) function.

Methods

Forty rats were given the GnRH analog buserelin (20 μg, 1 mg/ml) or saline subcutaneously, once daily for 5 days, followed by 3 weeks of recovery, representing one treatment session. Two weeks after the fourth treatment session, the animals were tested for GI transit time and galactose absorption, and fecal weight and fat content was analyzed. After sacrifice, enteric neuronal subpopulations were analyzed. Blood samples were analyzed for zonulin and antibodies against GnRH and luteinizing hormone, and their receptors.

Results

Buserelin treatment transiently increased the body weight after 5 and 9 weeks (p < 0.001). Increased estradiol in plasma and thickened uterine muscle layers indicate high estrogen activity. The numbers of both submucous and myenteric neurons were reduced by 27%–61% in ileum and colon. The relative numbers of neurons containing calcitonin gene-related peptide (CGRP), cocaine- and amphetamine-related transcript (CART), galanin, gastrin-releasing peptide (GRP), neuropeptide Y (NPY), nitric oxide synthase (NOS), serotonin, substance P (SP), vasoactive intestinal peptide (VIP) or vesicular acetylcholine transporter (VAchT), and their nerve fiber density, were unchanged after buserelin treatment, but the relative number of submucous neurons containing somatostatin tended to be increased (p = 0.062). The feces weight decreased in buserelin-treated rats (p < 0.01), whereas feces fat content increased (p < 0.05), compared to control rats. Total GI transit time, galactose absorption, zonulin levels in plasma, and antibody titers in serum were unaffected by buserelin treatment.

Conclusions

A marked enteric neuronal loss with modest effects on GI function is found after buserelin treatment. Increased feces fat content is suggested an early sign of dysfunction.

【 授权许可】

   
2014 Sand et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 6.

【 参考文献 】

• [1]Ohlsson B, Veréss B, Janciauskiene S, Montgomery A, Haglund M, Wallmark A: Chronic intestinal pseudo-obstruction due to buserelin-induced formation of anti-GnRH antibodies. Gastroenterology 2007, 132:45-51.
• [2]Hammar O*, Ohlsson B*, Veress B, Nordin Fredrikson G, Alm R, Montgomery A: Depletion of enteric gonadotropin-releasing hormone is found in a few patients suffering from severe gastrointestinal dysmotility. Scand J Gastroenterol 2012, 47:1165-1173. * = Both are first authors
• [3]Hammar O, Roth B, Bengtsson M, Mandl T, Ohlsson B: Autoantibodies and gastrointestinal symptoms in infertile women in relation to in vitro fertilization. BMC Pregnancy Childbirth 2013, 13:201. BioMed Central Full Text
• [4]Sand E, Voss U, Hammar O, Nordin Fredrikson G, Alm R, Ohlsson B, Ekblad E: Gonadotropin-releasing hormone analog buserelin causes neuronal loss in rat gastrointestinal tract. Cell Tissue Res 2013, 351:521-534.
• [5]Ohlsson B, Sand E, Veress B: Ganglioneuritis is common in rats with enteric neuropathy due to buserelin treatment. Regul Pept 2014, 190–191:43-45.
• [6]Furness JB: The Enteric Nervous System. Blackwell Publish Ltd, Oxford; 2006.
• [7]Ekblad E, Mulder H, Sundler F: Vasoactive intestinal peptide expression in enteric neurons is upregulated by both colchicine and axotomy. Regul Pept 1996, 63:113-121.
• [8]Ekblad E, Sjuve R, Arner A, Sundler F: Enteric neuronal plasticity and a reduced number of interstitial cells of Cajal in hypertrophic rat ileum. Gut 1998, 42:836-844.
• [9]Lindeström LM, Ekblad E: Structural and neuronal changes in rat ileum after ischemia with reperfusion. Dig Dis Sci 2004, 49:1212-1222.
• [10]Arciszewski MB, Barabasz S, Całka J: Immunohistochemical localization of galanin receptors (GAL-R1, GAL-R2, and GAL-R3) on myenteric neurons from the sheep and dog stomach. Ann Anat 2008, 190:360-367.
• [11]Sand E, Themner-Persson A, Ekblad E: Infiltration of mast cells in rat colon is a consequences of ischemia/reperfusion. Dig Dis Sci 2008, 53:3158-3169.
• [12]Belai A, Boulos PB, Robson T, Burnstock G: Neurochemical coding in the small intestine of patients with Crohn’s disease. Gut 1997, 40:767-774.
• [13]Schneider J, Jehle EC, Starlinger MJ, Neunlist M, Michel K, Hoppe S, Schemann M: Neurotransmitter coding of enteric neurons in the submucous plexus is changed in non-inflamed rectum of patients with Crohn’s disease. Neurogastroenterol Motil 2001, 13:255-264.
• [14]Vera G, Castillo M, Cabezos PA, Chiarlone A, Martín MI, Gori A, Pasquinelli G, Barbara G, Stanghellini V, Corinaldesi R, De Giorgio R, Abalo R: Enteric neuropathy evoked by repeated cisplatin in the rat. Neurogastroenterol Motil 2011, 23:370-378.
• [15]Voss U, Sand E, Olde B, Ekblad E: Enteric neuropathy can be induced by high fat diet in vivo and palmitic acid exposure in vitro. PLoS One 2013, 8:e81413.
• [16]Demedts I, Masaoka T, Kindt S, De Hertogh G, Geboes K, Farré R, Vanden Berghe P, Tack J: Gastrointestinal motility changes and myenteric plexus alterations in spontaneously diabetic biobreeding rats. J Neurogastroenterol Motil 2013, 19:161-170.
• [17]Trindade CR, Camargos AF, Pereira FEL: The effect of buserelin acetate on the uterus of adult rats: morphological aspects. Clin Exp Obstet Gynecol 2008, 3:198-201.
• [18]Freeman ME: Neuroendocrine Control of the Ovarian Cycle of rat. In Knobil and Neill’s Physiology of Reproduction. 3rd edition. Edited by Neill JD, Plant TM, Pfaff DW, Challis JRG, Kretser DM, Richards JS, Wassarman PM. Elsevier, Amsterdam; 2006:2328-2329.
• [19]Maldonado-Devinccci AM, Alipour KK, Michael LA, Kirstein CL: Repeated binge ethanol administration during adolescence enhances voluntary sweetened ethanol intake in young adulthood in male and female rats. Pharmacol Biochem Behav 2010, 96:476-487.
• [20]Ekblad E, Kuhar M, Wierup N, Sundler F: Cocaine- and amphetamine-regulated transcript: distribution and function in rat gastrointestinal tract. Neurogastroenterol Motil 2003, 15:545-557.
• [21]Zacharko-Siembida A, Kulik P, Szalak R, Lalak R, Arciszewski MB: Co-expression patterns of cocaine- and amphetamine-regulated transcript (CART) with neuropeptides in dorsal root ganglia of the pig. Acta Histochem 2014, 116:390-398.
• [22]Ekblad E, Ekman R, Håkanson R, Sundler F: Projections of peptide-containing neurons in rat colon. Neurosci 1988, 27:655-674.
• [23]Lin Z, Sandgren K, Ekblad E: Increased expression of vasoactive intestinal peptide in cultured myenteric neurons from rat small intestine. Auton Neurosci 2003, 107:9-19.
• [24]Ekblad E, Alm P, Sundler F: Distribution, origin and projections of nitric oxide synthase-containing neurons in gut and pancreas. Neuroscience 1994, 63:233-248.
• [25]Kristensson E, Themner-Persson A, Ekblad E: Distribution, origin and projections of nitric oxide synthase-containing neurons in gut and pancreas. Regul Pept 2007, 140:109-116.
• [26]Mulder H, Ekelund M, Ekblad E, Sundler F: Islet amyloid polypeptide in the gut and pancreas: localization, ontogeny and gut motility effects. Peptides 1997, 18:771-783.
• [27]Lindeström LM, Ekblad E: Origins and projections of nerve fibers in rat pyloric sphincter. Auto Neurosci 2002, 97:73-82.
• [28]Qian BF, Hammarström ML, Danielsson A: Differential expression of vasoactive intestinal polypeptide receptor 1 and 2 mRNA in murine intestinal T lymphocyte subtypes. J Neuroendocrinol 2001, 13:818-825.
• [29]Arvidsson U, Riedl M, Elde R, Meister B: Vesicular acetylcholine transporter (VAChT) protein: a novel and unique marker for cholinergic neurons in the central and peripheral nervous systems. J Comp Neurol 1997, 378:454-467.
• [30]Montelius C, Gustafsson K, Weström B, Albertsson PÅ, Emek SC, Rayner M: Erlansson-Albertsson: Chloroplast thylakoids reduce glucose uptake and decrease intestinal macromolecular permeability. Br J Nutr 2011, 106:836-844.
• [31]Thymann T, Burrin DG, Tappenden KA, Bjornvad CR, Jensen SK, Sangild PT: Formula-feeding reduces lactose digestive capacity in neonatal pigs. Brit J Nutr 2006, 95:1075-1081.
• [32]Vanner S, Macnaughton WK: Submucosal secretomotor and vasodilator reflexes. Neurogastroenterol Motil 2004, 16(Suppl 1):39-43.
• [33]Ekblad E, Winther C, Ekman R, Håkanson R, Sundler F: Projections of peptide-containing neurons in rat small intestine. Neuroscience 1987, 20:169-188.
• [34]Ratnayake WM, Galli C: Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Ann Nutr Metab 2009, 55:8-43.
• [35]Mourad FH, Saadé NE: Neural regulation of intestinal nutrient absorption. Prog Neurobiol 2011, 95:149-162.
• [36]Hammar O, Veress B, Montgomery A, Ohlsson B: Expression of luteinizing hormone receptor in the gastrointestinal tract in patients with and without dysmotility. DTI 2012, 6:13-18.
• [37]Wright EM, Loo DD, Hirayama BA: Biology of human sodium glucose transporters. Physiol Rev 2011, 91:733-794.
• [38]Cura AJ, Carruthers A: Role of monosaccharide transport proteins in carbohydrate assimilation, distribution, metabolism, and homeostasis. Compr Physiol 2012, 2:863-914.
• [39]Belchetz PE, Plnt TM, Nakai Y, Keogh EJ, Knobil E: Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978, 202:631-633.
• [40]Roa J, Vigo E, Castellano JM, Navarro VM, Fernández-Fernández R, Casanueva FF, Dieguez C, Aguilar E, Pinilla L, Tena-Sempere M: Hypothalamic expression of KiSS-1 system and gonadotropin-releasing effects of kisspeptin in different reproductive states of the female rat. Endocrinology 2006, 147:2864-2878.
• [41]Salehi MS, Jafarzadeh Shirazi MR, Zamiri MJ, Pazhoohi F, Namavar MR, Niazi A, Ramezani A, Tanideh N, Tamadon A, Zarei A: Hypothalamic expression of KiSS1 and RFamide-related Peptide-3 mRNAs during the estrous cycle of rats. Int J Fertil Steril 2013, 6:304-309.
• [42]Naor Z: Signalling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor. Front Neuroendocrinol 2009, 30:10-29.
• [43]Campbell-Thompson M, Reyher KK, Wilkinson LB: Immunolocalization of estrogen receptor alpha and beta in gastric epithelium and enteric neurons. J Endocrinol 2001, 171:65-73.
• [44]Fasano A: Zonulin, regulation of tight junctions, and autoimmune diseases. Ann N Y Acad Sci 2012, 1258:25-33.
• [45]Canavan C, West J, Card T: The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014, 6:71-80.
• [46]Hughes PA, Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D: Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol 2013, 108:1066-1074.
• [47]Crane C, Martin M: Perceived vulnerability to illness in individuals with irritable bowel syndrome. J Psychosom Res 2002, 53:1115-1122.
• [48]Drossman DA, McKee DC, Sandler RS, Mitchell CM, Cramer EM, Lowman BC, Burger AL: Psychological factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988, 95:701-708.
• [49]Dorn SD, Palsson OS, Thiwan SI, Kanazawa M, Clark WC, van Tilburg MA, Drossman DA, Scarlett Y, Levy RL, Ringel Y, Crowell MD, Olden KW, Whitehead WE: Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007, 56:1202-1209.
• [50]Elsenbruch S, Rosenberger C, Enck P, Forsting M, Schedlowski M, Gizewski ER: Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 2010, 59:489-495.
• [51]Larsson MB, Tillisch K, Craig AD, Engström M, Labus J, Naliboff B, Lundberg P, Ström M, Mayer EA, Walter SA: Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome. Gastroenterology 2012, 142:463-472. e3
• [52]Keszthelyi D, Troost FJ, Jonkers DM, Helyes Z, Hamer HM, Ludidi S, Vanhoutvin S, Venema K, Dekker J, Szolcsányi J, Masclee AA: Alterations in mucosal neuropeptides in patients with irritable bowel syndrome and ulcerative colitis in remission: a role in pain symptom generation? Eur J Pain 2013, 9:1299-1306.